The goal of this pragmatic, multi-centre factorial cluster randomized cross-over trial is to assess the efficacy of a combination of cefazolin plus vancomycin compared to cefazolin monotherapy, as well as a comparison of short versus long-term prophylaxis with four study arms: 1) cefazolin short-term, 2) cefazolin long-term, 3) cefazolin plus vancomycin short-term and 4) cefazolin plus vancomycin long-term.
None
On systemic antibiotics or with an active bacterial infection at the time of surgery
Previously enrolled in this trial
Known to be colonized with methicillin-resistant staphylococcus aureus (MRSA). Where it is unethical to not administer glycopeptides.
Beta-lactam or vancomycin allergy precluding the use of cefazolin or vancomycin, respectively
Hamilton Health Sciences Corporation
Lead sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator